

Workshop South

Shouval	Daniel	Israel
Socan	Mana	Slovenia
Bonanni	Paolo	Italy
Dominguez	Angela	Spain
Marinho	Rui Tato	Portugal
Papaevangelou	Vana	Greece
Zanetti	Alessandro	Italy



What still needs to be done in the prevention and control of viral hepatitis

1) HBV

- Better surveillance of chronic hepatitis and HCC.
- Good vaccination coverage. More efforts to guarantee the sustainability .
 - Improve coverage of birth dose,
 - Better screening of pregnant women,
 - Respond to increased activity of anti vaccination groups
 - Increase awareness and implementation of the guidelines
 - Communicate success stories



What still needs to be done in the prevention and control of viral hepatitis

HCV

- Better understanding of national history of HCV
- Introduction of a notification system, national registries and surveillance of chronic hepatitis and HCC.
- Pilot studies to know the prevalence of anti- HCV in the population and the cost of universal screening.
- Screening is recommended provided there are resources to treat the identified individuals.
- Promote harm reduction actions eg disposable needles, etc..
- To promote education international precaution measures for HCW
- Sustain the safety measures (NAT) of blood supply.



What still needs to be done in the prevention and control of viral hepatitis

HAV

- Recommend HAV vaccination of persons traveling to relatives .
- Implementation of MSM vaccination and other risk groups.



What do you expect from the international organisation

- Verification of official reported coverage data.
- Communicate success stories
- Encourage member states to improve screening surveillance of HCV and HBV provided that these countries are able to cover the costs of treatment in those individuals identified.
- Preparation of toolkits and factsheets in the individual languages of the member states.
- Promotion of a pan-European consortium(a) involving patient organisations to negotiate affordable prices for drugs and vaccines.
- Introduce the idea of possible eradication of HBV and HAV by vaccination.
- Increase awareness of “emerging” HEV infections
- Need for validated tests for HEV sero-prevalence studies.

